Identification and Assessment of Risk Factors for the Development of Osteoporosis in Adults and Children Living in the Abay Region of the Republic of Kazakhstan Using the Method of Dual-energy X-ray Absorptiometry and Clinical and Epidemiological Research

March 27, 2024 updated by: Semey State Medical University

Clinical and Epidemiological Risk Evaluation of Osteoporosis Prevalence at Different Ages With to Assess Bone Quantification Using Dual-energy X-ray Absorptiometry

A survey of people to identify risk factors for osteoporosis, which include age, gender, lifestyle, diet, physical activity, the presence or absence of somatic pathology. Diagnosis of osteoporosis by dual-energy X-ray absorptiometry. Conducting a correlation analysis of the relationship of the data obtained.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Successful diagnosis of osteoporosis is possible with the complex use of clinical, laboratory and radiological methods. In the complex of diagnostic methods, a special place has given to dual-energy X-ray absorptiometry, which is the "gold standard". The research area contains the following tasks:

Risk factors for the development of osteoporosis will be identified and quantified in the formed study groups of adults; to determine the diagnostic value of the risk factors for the development of osteoporosis obtained during the examination.

to assess the state of BMD in adults using X-ray absorptiometry (DXA) To carry out a correlation analysis of the relationship between the obtained data in adults of the Abay region of of the Republic of Kazakhstan

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Residents of the Abay region of the Republic of Kazakhstan

Description

Inclusion Criteria: adults and children without a history of pathological fractures and congenital pathology of the musculoskeletal system.

-

Exclusion Criteria: adults and children with congenital pathology of the musculoskeletal system

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Persons with normal BMD
Persons with low BMD

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Risk factors for the development of osteoporosis will be identified and quantified in the formed study groups of adults
Time Frame: By the end of Dec 2025
By the end of Dec 2025
to determine the diagnostic value of the risk factors for the development of osteoporosis obtained during the examination
Time Frame: By the end of Dec 2025
By the end of Dec 2025
to assess the state of BMD in adults using X-ray absorptiometry (DXA)
Time Frame: By the end of Dec 2025
By the end of Dec 2025
To carry out a correlation analysis of the relationship between the obtained data in adults of the Abay region of of the Republic of Kazakhstan
Time Frame: By the end of Dec 2025
By the end of Dec 2025

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Semey State Medical University

Collaborators

Ministry of Science and Higher Education of the Republic of Kazakhstan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Estimated)

November 15, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

March 27, 2024

First Submitted That Met QC Criteria

March 27, 2024

First Posted (Actual)

April 3, 2024

Study Record Updates

Last Update Posted (Actual)

April 3, 2024

Last Update Submitted That Met QC Criteria

March 27, 2024

Last Verified

September 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0123РК00314
  • AP19680262 (Other Identifier: Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe